SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Commonsense Ways to work on Your Funds with a Restricted Pay - 2Kansas school officials report high student illness, dismiss early
- 3Grasping the Qualifications Among Separation and Dissolution
- 4Collierville residents with no power as temperatures plunge
- 5A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- Vote in favor of Your Number one Smartwatch: Exactness and Style Matter
- See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- RFK Jr. guts the US childhood vaccine schedule despite its decades-long safety record
- Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- Figure out How to Protect Your Gold Venture from Unpredictability
- Step by step instructions to Pick the Right Web-based Degree Program
- What do teens and tweens want for the holidays? E-bikes, gift cards and lip tints.
- Watch the Geminid meteor shower peak tonight from the comfort of home with this free livestream
